Scientists have begun Clinical Trials to come up with possible vaccine for Coronavirus vaccine.
It will take 12 to 18 months to roll out a Corona vaccine as expected by the pharmaceutical companies, executives said on Thursday, as they jointly pledged to make it available worldwide based on need.
Despite the need for urgent Coronavirus vaccine , safety trials will not be compromised in any case. Safe testings in clinical trials will be met with proper investigations, as told by industry chiefs and the International Federation of Pharmaceutical Manufacturers and Associations in a virtual press conference hosted in Geneva.
IFPMA president David Ricks, the chairman of Eli Lilly and Company assured in a conference that modern advances in technology and medicine will definately play a vast role in coming up for a Coronavirus vaccine to tackle this outbreak in a short time.
The global death toll for Coronavirus is now about to reach 11,000 with more than 255,190 confirmed infections, based on official sources.
“Once the Coronavirus vaccine is made the next challange will be to vaccinate people around the world and we’re talking billions,” said David Loew, the executive vice president of Sanofi Pasteur.
As of today the first trial for Coronavirus vaccine in human has already begun from Monday 16 March, 2020. the need of the hour has forced us to skip the animal trials and directly begin testing on humans Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases, said in a statement Monday. “This Phase 1 study, launched in record speed, is an important first step toward achieving that goal.”
The trials are taking place at the Kaiser Permanente Washington Health Research Institute in Seattle, Washington. Phase 1 trials will test the Coronavirus vaccine on 45 males and non pregnant females from the ages of 18 to 55.
Fauci has said the potential Coronavirus vaccine contains genetic material called messenger RNA. The mRNA is a genetic code that tells cells how to make a protein and was found in the outer coat of the new Coronavirus , according to researchers at the Kaiser Permanente Washington Health Research Institute.
Developing, testing and reviewing any potential vaccine is a long, complex and expensive endeavor that could take months or even years, global health experts say.
“You’re injecting this into healthy people to test the safety of vaccine in healthy individuals to check for any unnecessary effects,” .”It could also have harmful effects on other vaccines, if people lose trust in vaccination,” Leow added.
“The regulatory authorities are proving to be helpful by removing several restrictions on research laboratories to escalate the process of Coronavirus vaccine testing and getting in market for quicker relief .”
Venkayya added that some, if not most of the testing programmes being run, would fail to produce a viable vaccine. However, the value of running multiple trials simultaneously was that “some will succeed and get across the finish line”, he said.
Venkayya said the industry would prioritize access and equal distribution of Coronavirus vaccine to everyone who need it across the globe” as said by Paul Stoffels, chief scientific officer at Johnson and Johnson .
Stoffels said the problem in reaching solutions was that the virus had new characteristics compared to outbreaks such as SARS.
“This virus is extremely transmittable quite different from SARS so we need new approaches starting from scratch.”
Money will not be an issue as whole of the industry unites at one point to develop effective vaccine and to distribute among whoever is in meed of it.
Ricks said nobody in the industry is talking about taking credit or making money out of Coronavirus vaccine,” It is a time of dire need for all mankind and such petty behavior will not be tolerated”, public and private partnerships with industries will help cover for cost of this expensive – in time and money- process.
IFPMA director-general Thomas Cueni said the industry was putting on an unprecedented united front to conquer the virus.
Fauci told reporters last month a vaccine may not solve “problems in the next couple of months but it certainly would be an important tool that we would have.”